Citadel Advisors’s Biocept, Inc. BIOC Stock Holding History

Citadel Advisors’s Portfolio BIOC Stock Details BIOC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3	Closed	-$34	–	15697
2023 Q1	$34	Sell	3 -4	-57%	-$58	﹤0.01%	14614
2022 Q4	$106	Buy	+7	New	+$154	﹤0.01%	14759
2022 Q2	–	Sell	-373	Closed	-$26K	–	14601
2022 Q1	$26K	Buy	+373	New	+$29.3K	﹤0.01%	13167
2021 Q3	–	Sell	-4,303	Closed	-$541K	–	14982
2021 Q2	$541K	Sell	4,303 -1,860	-30%	-$252K	﹤0.01%	9899
2021 Q1	$941K	Buy	+6,163	New	+$1.12M	﹤0.01%	8281
2015 Q4	–	Hold	0	–	-$5K	–	9351
2015 Q3	–	Hold	0	–	–	–	8644

Other funds holding BIOC

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's BIOC Position: Q2 2023 in Review

Citadel Advisors sold out of Biocept, Inc. (BIOC) in Q2 2023, closing a stake of 274 shares — an estimated $2.79K sold.

Citadel Advisors first reported a position in BIOC in Q3 2015 and held it in 14 quarters. The position peaked at $203K in Q4 2021. 11 funds tracked by Wall St. Rank hold BIOC as of Q2 2023.

Citadel Advisors reported no remaining Biocept, Inc. position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 274 Biocept, Inc. shares in Q2 2023, an estimated $2.79K.
Citadel Advisors first reported a position in Biocept, Inc. in Q3 2015 and held it in 14 quarters.
Citadel Advisors's Biocept, Inc. position peaked at $203K in Q4 2021.
11 funds tracked by Wall St. Rank held Biocept, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.